Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element
- 15 December 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (13) , 4369-4376
- https://doi.org/10.1182/blood-2003-05-1762
Abstract
Hematopoiesis is a complex process involving hematopoietic stem cell (HSC) self-renewal and lineage commitment decisions that must continue throughout life. Establishing a reproducible technique that allows for the long-term ex vivo expansion of human HSCs and maintains self-renewal and multipotential differentiation will allow us to better understand these processes, and we report the ability of the leukemia-associated AML1-ETO fusion protein to establish such a system. AML1-ETO-transduced human CD34+ hematopoietic cells routinely proliferate in liquid culture for more than 7 months, remain cytokine dependent for survival and proliferation, and demonstrate self-renewal of immature cells that retain both lymphoid and myeloid potential in vitro. These cells continue to express the CD34 cell surface marker and have ongoing telomerase activity with maintenance of telomere ends, however they do not cause leukemia in nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice. Identification of the signaling pathways that are modulated by AML1-ETO and lead to the self-renewal of immature human progenitor cells may assist in identifying compounds that can efficiently expand human stem and progenitor cells ex vivo. (Blood. 2003; 102:4369-4376)Keywords
This publication has 38 references indexed in Scilit:
- A Stem Cell Molecular SignatureScience, 2002
- "Stemness": Transcriptional Profiling of Embryonic and Adult Stem CellsScience, 2002
- Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cellsBlood, 2002
- Stem cells, cancer, and cancer stem cellsNature, 2001
- Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact systemBlood, 2001
- Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord bloodLeukemia, 2000
- Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteinsBlood, 2000
- Long-Term Ex Vivo Maintenance and Expansion of Transplantable Human Hematopoietic Stem CellsBlood, 1999
- Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cellsProceedings of the National Academy of Sciences, 1998
- Stroma-Contact Prevents Loss of Hematopoietic Stem Cell Quality During Ex Vivo Expansion of CD34+ Mobilized Peripheral Blood Stem CellsBlood, 1998